WO2002098856A3 - Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists - Google Patents
Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists Download PDFInfo
- Publication number
- WO2002098856A3 WO2002098856A3 PCT/US2002/017821 US0217821W WO02098856A3 WO 2002098856 A3 WO2002098856 A3 WO 2002098856A3 US 0217821 W US0217821 W US 0217821W WO 02098856 A3 WO02098856 A3 WO 02098856A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- naphthaline
- oxyquinoline
- piperazine
- adenosine diphosphate
- receptor antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003501845A JP4409936B2 (en) | 2001-06-06 | 2002-06-06 | Platelet adenosine diphosphate receptor antagonist |
EP02746471A EP1412349A2 (en) | 2001-06-06 | 2002-06-06 | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists |
AU2002316191A AU2002316191A1 (en) | 2001-06-06 | 2002-06-06 | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29649801P | 2001-06-06 | 2001-06-06 | |
US60/296,498 | 2001-06-06 | ||
US10/163,742 | 2002-06-05 | ||
US10/163,742 US6861424B2 (en) | 2001-06-06 | 2002-06-05 | Platelet adenosine diphosphate receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002098856A2 WO2002098856A2 (en) | 2002-12-12 |
WO2002098856A3 true WO2002098856A3 (en) | 2004-03-04 |
Family
ID=26859907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/017821 WO2002098856A2 (en) | 2001-06-06 | 2002-06-06 | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists |
Country Status (5)
Country | Link |
---|---|
US (4) | US6861424B2 (en) |
EP (1) | EP1412349A2 (en) |
JP (1) | JP4409936B2 (en) |
AU (1) | AU2002316191A1 (en) |
WO (1) | WO2002098856A2 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
OA12970A (en) * | 2002-12-11 | 2006-10-13 | Schering Ag | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists. |
US7488739B2 (en) * | 2003-07-24 | 2009-02-10 | Astellas Pharma Inc. | Quinolone derivative or salt thereof |
CA2581638A1 (en) * | 2004-09-29 | 2006-04-13 | Portola Pharmaceuticals, Inc. | Substituted 2h-1,3-benzoxazin-4(3h)-ones |
TW200640877A (en) * | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
EP1920048A4 (en) * | 2005-07-29 | 2009-12-09 | Childrens Hosp Medical Center | Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase |
JP4976394B2 (en) * | 2005-08-17 | 2012-07-18 | シェーリング コーポレイション | A novel high affinity quinoline-based kinase ligand |
AR057836A1 (en) | 2005-10-21 | 2007-12-19 | Actelion Pharmaceuticals Ltd | PIPERIZINAS AS AGENTS AGAINST MALARIA |
US7615556B2 (en) * | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
TWI391378B (en) | 2006-03-16 | 2013-04-01 | Astellas Pharma Inc | Quinolone derivative or pharmaceutically acceptable salt thereof |
EP1999117A2 (en) * | 2006-03-29 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
US20070254861A1 (en) * | 2006-04-28 | 2007-11-01 | Astellas Pharma Inc. | Methods for the prevention and/or treatment of peripheral arterial disease |
CL2007002920A1 (en) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | COMPOUNDS DERIVED FROM 2-AMINOCARBONYLPIRIDINE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS. |
CL2007003038A1 (en) * | 2006-10-25 | 2008-06-06 | Actelion Pharmaceuticals Ltd | COMPOUNDS DERIVED FROM 2-PHENYL-6-AMINOCARBONIL-PYRIMIDINE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS. |
EP1967513A1 (en) * | 2007-03-08 | 2008-09-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel P2Y12 receptor antagonists |
WO2008128647A1 (en) * | 2007-04-23 | 2008-10-30 | Sanofi-Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
WO2008155022A1 (en) | 2007-06-18 | 2008-12-24 | Sanofi-Aventis | Pyrrole derivatives as p2y12 antagonists |
RU2483072C2 (en) * | 2007-11-29 | 2013-05-27 | Актелион Фармасьютиклз Лтд | Phosphonic acid derivatives and use thereof as p2y12 receptor antagonists |
EP2238128B1 (en) | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
AR071652A1 (en) * | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | DERIVATIVES 2- SUBSTITUTED PHENYL-PYRIDINE |
AR071653A1 (en) * | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | DERIVATIVES 2-FENIL-4-CICLOPROPIL-PYRIMIDINE |
US20130303477A1 (en) | 2008-05-13 | 2013-11-14 | The Medicines Company | Maintenance of Platelet Inhibition During Antiplatelet Therapy |
WO2009140092A1 (en) | 2008-05-13 | 2009-11-19 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
US8759316B2 (en) | 2008-05-13 | 2014-06-24 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
US20120141468A1 (en) | 2008-05-13 | 2012-06-07 | Lisa Ruderman Chen | Maintenance of platelet inhibition during antiplatelet therapy |
US9427448B2 (en) | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
WO2010075356A1 (en) * | 2008-12-23 | 2010-07-01 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
BRPI1014039A2 (en) | 2009-04-08 | 2018-04-03 | Actelion Pharmaceuticals Ltd | 6- (3-aza-bicyclo [3.1.0] hex-3-yl) -2-phenyl-pyrimidines |
NZ596388A (en) | 2009-04-22 | 2013-05-31 | Actelion Pharmaceuticals Ltd | Thiazole derivatives and their use as p2y12 receptor antagonists |
US8729095B2 (en) | 2009-08-28 | 2014-05-20 | Daiichi Sankyo Company, Limited | 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases |
CA2778880C (en) | 2009-11-11 | 2018-02-13 | The Medicines Company | Methods of treating or preventing stent thrombosis |
US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
JP2013512246A (en) | 2009-11-25 | 2013-04-11 | メルク・シャープ・アンド・ドーム・コーポレーション | Condensed tricyclic compounds and derivatives useful for the treatment of viral diseases |
US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
US8889688B2 (en) | 2010-01-05 | 2014-11-18 | Actelion Pharmaceuticals Ltd. | Piperazines as antimalarial agents |
JP2013522202A (en) | 2010-03-09 | 2013-06-13 | メルク・シャープ・エンド・ドーム・コーポレイション | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
WO2013039876A1 (en) | 2011-09-14 | 2013-03-21 | Merck Sharp & Dohme Corp. | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
GB201218084D0 (en) * | 2012-10-09 | 2012-11-21 | Univ Aston | Novel compounds and methods for use in medicine |
CN105189485B (en) | 2013-03-15 | 2017-10-24 | 埃科特莱茵药品有限公司 | It is used as the novel propylene amide derivatives of anti-malarial agents |
EP3515924B1 (en) | 2016-09-22 | 2021-12-15 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
CN110381947A (en) | 2017-03-15 | 2019-10-25 | 爱杜西亚药品有限公司 | P2Y12The subcutaneous administration of receptor antagonist |
MA49452A (en) | 2017-06-23 | 2021-05-05 | Chiesi Farm Spa | METHOD FOR PREVENTING SHUNT THROMBOSIS OF THE SYSTEMIC-PULMONARY ARTERY |
EP4031542A4 (en) * | 2019-09-18 | 2023-10-25 | Merck Sharp & Dohme LLC | Small molecule inhibitors of kras g12c mutant |
MX2022005053A (en) | 2019-10-28 | 2022-05-18 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant. |
US11945790B2 (en) * | 2020-12-22 | 2024-04-02 | Immunomolecular Therapeutics, Inc. | Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992008709A1 (en) * | 1990-11-15 | 1992-05-29 | Pentapharm Ag | Meta-substituted phenyl alanine derivatives |
EP0739886A2 (en) * | 1995-04-28 | 1996-10-30 | LG Chemical Limited | Selective thrombin inhibitors |
WO1998056771A2 (en) * | 1997-06-12 | 1998-12-17 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1334705A (en) | 1970-06-19 | 1973-10-24 | Ici Ltd | Pharmaceutical compositions containing kynurenic acid derivatives |
US4258192A (en) | 1977-12-16 | 1981-03-24 | Mitsubishi Chemical Industries Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US5346907A (en) | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
AU5878194A (en) | 1993-02-10 | 1994-08-29 | Pentapharm Ag | Piperazides of substituted phenylalanine derivates as thrombin inhibitors |
JP2003502314A (en) * | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | Compound |
-
2002
- 2002-06-05 US US10/163,742 patent/US6861424B2/en not_active Expired - Fee Related
- 2002-06-06 JP JP2003501845A patent/JP4409936B2/en not_active Expired - Fee Related
- 2002-06-06 EP EP02746471A patent/EP1412349A2/en not_active Withdrawn
- 2002-06-06 WO PCT/US2002/017821 patent/WO2002098856A2/en active Application Filing
- 2002-06-06 AU AU2002316191A patent/AU2002316191A1/en not_active Abandoned
-
2004
- 2004-09-22 US US10/947,579 patent/US7026323B2/en not_active Expired - Fee Related
- 2004-09-22 US US10/947,635 patent/US6995156B2/en not_active Expired - Fee Related
-
2006
- 2006-02-02 US US11/347,768 patent/US7176207B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992008709A1 (en) * | 1990-11-15 | 1992-05-29 | Pentapharm Ag | Meta-substituted phenyl alanine derivatives |
EP0739886A2 (en) * | 1995-04-28 | 1996-10-30 | LG Chemical Limited | Selective thrombin inhibitors |
WO1998056771A2 (en) * | 1997-06-12 | 1998-12-17 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
Non-Patent Citations (3)
Title |
---|
DULLWEBER,F. ET AL.: "Factorising Ligand Affinity : A Combined Thermodynamic and Crysstallographic Study of Trypsin and Thrombin Inhibition", J.MOL.BIOL., vol. 313, 2001, pages 593 - 614, XP002226502 * |
KAMM,W. ET AL.: "Transport of Peptidomimetic Thrombin Inhibitors with a 3-amidino-Phenylalanine Structure : Permeability and Efflux Mechanism in Monolayers of a Human Intestinal Cell Line (Caco-2)", PHARM.RES., vol. 18, no. 8, 2001, pages 1110 - 1118, XP009003114 * |
PIERCE,A.C ET AL.: "Estimation of Binding Affinities for Selective Thrombin Inhibitors via Monte Carlo Simulations", J.MED.CHEM., vol. 44, no. 7, 2001, WASHINGTON, pages 1043 - 1050, XP002226501 * |
Also Published As
Publication number | Publication date |
---|---|
US7176207B2 (en) | 2007-02-13 |
WO2002098856A2 (en) | 2002-12-12 |
US7026323B2 (en) | 2006-04-11 |
US6861424B2 (en) | 2005-03-01 |
JP4409936B2 (en) | 2010-02-03 |
US20050038037A1 (en) | 2005-02-17 |
US20030060474A1 (en) | 2003-03-27 |
AU2002316191A1 (en) | 2002-12-16 |
US6995156B2 (en) | 2006-02-07 |
US20060135532A1 (en) | 2006-06-22 |
JP2004532886A (en) | 2004-10-28 |
US20050065163A1 (en) | 2005-03-24 |
EP1412349A2 (en) | 2004-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002098856A3 (en) | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists | |
WO2003086303A3 (en) | Farnesoid x-activated receptor agonists | |
DE60204452D1 (en) | [1,5] pyridine derivatives | |
SE9904652D0 (en) | Novel Compounds | |
DK0911333T3 (en) | Pyrazole [4,3-d] pyrimidine derivatives and pharmaceutical compositions containing them | |
DE60112609D1 (en) | Pyrazolopyridine | |
NO20052496L (en) | Selected CGRP antagonists, methods for their preparation and use thereof as drugs. | |
WO2001042219A3 (en) | Novel substituted phenanthridinones and methods of use thereof | |
HK1155146A1 (en) | Indene derivatives as pharmaceutical agents | |
BG103485A (en) | Ketobanzamides as calpain inhibitors | |
EP1253142A4 (en) | Compounds exhibiting thrombopoietin receptor agonism | |
NO20025821L (en) | 2-aminocarbonyl-9H-purine | |
IL143545A0 (en) | Thrombin inhibitors | |
WO2003095455A3 (en) | Substituted pyrazolopyrimidines | |
CA2390649A1 (en) | 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them | |
TR200101155T2 (en) | 4-Aroil Piperidine CCR-3 Receptor Antagonists III | |
WO2003002489A3 (en) | Solid-phase electrophilic fluorination | |
WO2002048148A3 (en) | Pyrazolopyridine derivatives | |
RS20050450A (en) | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists | |
WO2004082623A3 (en) | Substituted piperidine compounds | |
WO2004112704A3 (en) | Substituted piperidine compounds and methods of their use | |
WO2003053971A8 (en) | Pyridoquinoxaline antivirals | |
MA26418A1 (en) | PIPERIDONES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
CA2412596A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
WO1999062893A3 (en) | Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002746471 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003501845 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002746471 Country of ref document: EP |